logo-with-company-name.svg

Capabilities

Our Expertise

Services

Target discovery

Drug Classes

Cooperation

Testimonials

Lead Selection

Lead Optimisation & Characterisation

Our Service Models

Strategic partnerships

Our Equipment

Product Characterisation

Our Team

Biosimilar Characterisation

Careers

News

Contact Us

Image showing Tim -Director of Molecular Biology 

Tim_London_author_100x100px.jpg

IndEx-2 research poster | Antibody Analytics 

<p>The research and time that has been put into our IndEx-2 platform has led to the development of a highly efficient inducible <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/best-practices-in-cell-line-development">cell line development tool</a>, packed with unique features and transformative capabilities.<br><br>This advanced inducible cell line model will accelerate the drug discovery process, through facilitating the determination of precise antigen density activation thresholds of targeted candidate immunotherapies early in the drug discovery phase. So now we are proud to present our research poster showing all the data you need to see how <strong>IndEx-2</strong> works.&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/202306%20I-O%20Summit%20London/Antibody%20Analytics%20%7C%20I-O%20Summit%20London%20%7C%20research%20poster%2001%20-%20Adele.pdf" target="_blank" class="external-btn-primary">Download our research poster</a></div></div><p><br>Approaches currently in use analyse and understand the impact of antigen density on therapeutic therapies rely on cell lines with varying levels. This can lead to slower research, which takes longer to deliver results.&nbsp;<br><br>IndEx-2, our <i>in vitro</i> cell-based platform allows the expression of one, or two, target antigens over a range of biologically relevant levels, facilitating the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies.<br><br>The data from across our research poster on IndEx-2 features key information, detailing the capabilities and actions that can be performed using this rapidly customisable and multi-purpose cell line development tool.&nbsp;<br><br>Access your very own copy of our informative research poster on IndEx-2 and feel free to get in touch with our experts if it piqued your interest:</p><p>&nbsp;</p><figure class="image image_resized" style="width:50%;"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/2023%20PEGS/Research%20posters/Antibody%20Analytics%20-%20Quantification%20of%20the%20antigen%20density%20activation%20threshold%20for%20targeted%20immunotherapeutics.pdf" target="_blank" rel="noopener noreferrer"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/image_a4394d357a.png"></a></figure><h2><br><br>Significance of target antigen density</h2><p>The multi-specific nature of bispecific antibody-based oncology therapeutics introduces many different layers of added complexity when looking to demonstrate appropriate levels of safety and efficacy.&nbsp;<br><br>There is currently a shortage of <i>in vitro</i> systems available to overcome this hurdle. Through our latest cell line development platform, <a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2">IndEx-2</a>, we have effectively demonstrated the overall integration capabilities and options to use this platform across multiple different types of assay formats.</p><h2>Understanding IndEx-2 and its capabilities</h2><p>To learn more about all the capabilities and applications of our <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/ind-ex-2-deciphering-the-impact-of-antigen-density-on-tumour-targeting-therapeutics">fully inducible cell line development platform</a>, speak to one of our scientists. Our experts can provide more details and information about the science behind IndEx-2, as well as the difference it can make when integrated with immune-oncology primary cell assays to provide a complete picture of a targeted drug candidate’s mechanism of action and safety profile.&nbsp;<br><br>If you would like to discuss the capabilities of IndEx-2, arrange a meeting with one of our experts here:<br>&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/lotta-hagi" target="_blank" class="external-btn-primary">Speak to a molecular biologist</a></div> </div>

IndEx-2 outline

IndEx-2 research poster image

Explore our research poster as we analyse the data from our new cell line development platform, IndEx-2. 

Index-2: Quantification of the antigen density activation threshold for targeted immunotherapeutics | Research poster

Robert Benson.jpg

Modelling the TME | Research poster

<p>Our world-class immunology team with the lead of our Scientific Director of Immunology, Robert Benson, has produced a research poster presenting <i>in vitro</i> primary human immune cell assays for assessing the effectiveness of new immuno-oncology therapies on various immune cell types.<br><br>Immunotherapy has transformed the treatment of cancer, allowing targeting and effective activation of the immune system to fight tumour cells. Despite success in some, not all patients respond to current therapies, warranting the need for new and more effective options.<br><br>Different subtypes of primary human immune cells, such as <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/treg-function-treg-suppression-and-your-therapeutic-candidate">regulatory T cells</a>,<strong> NK cells, </strong><a target="_blank" rel="noopener noreferrer" href="https://immunology.antibodyanalytics.com/macrophage-assays">macrophages</a>,<strong> T cells</strong>&nbsp;and <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/T-Cell-Exhaustion-Model-Agilent-Webinar">exhausted T cells</a><strong>,</strong> play important roles in the <strong>tumour microenvironment (TME) </strong>therefore assays using these cells can provide valuable insight into the evaluation of new immuno-oncology therapies.&nbsp;<br><br>In our <strong>research poster</strong> we share invaluable data showing various aspects of the tumour microenvironment and <i><strong>in vitro</strong></i><strong> assays</strong>.&nbsp;<br>Get your very own copy of our <strong>research poster</strong> here:<br>&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/202306%20I-O%20Summit%20London/Antibody%20Analytics%20%7C%20I-O%20Summit%20London%20%7C%20Research%20Poster%20%2002%20-%20Bob.pdf " target="_blank" class="external-btn-primary">Download our research poster </a></div></div><h2><br><strong>Improving immuno-oncology therapies</strong></h2><p><i>In vitro</i> assays with primary human immune cells are powerful tools for evaluating the impact of new immuno-oncology therapies on immune cell types that are relevant to cancer. These assays can help elucidate the mechanisms of action of the new therapies and assess their potential for clinical benefit, facilitating the discovery and development of new <strong>immuno-oncology therapies</strong> that can improve cancer treatment quality for patients.<br>&nbsp;</p><figure class="image image_resized" style="width:75%;"><a href="https://8176205.fs1.hubspotusercontent-na1.net/hubfs/8176205/202306%20I-O%20Summit%20London/Antibody%20Analytics%20%7C%20I-O%20Summit%20London%20%7C%20Research%20Poster%20%2002%20-%20Bob.pdf" target="_blank" rel="noopener noreferrer"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/image_b7cda7bd72.png"></a></figure><p>We can give you specialist support across a range of <i>in vitro</i> human bioassays specifically created for the tumour microenvironment covering regulatory T cells, macrophages, NK cells, T cells including exhausted and effector T cells and tumour cells.</p><p>If you have any questions regarding our research results presented in the poster or would like to discuss potential studies about the TME, feel free to reach out to our immunologists. &nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/lotta-hagi " target="_blank" class="external-btn-primary">Speak to an expert </a></div> </div>

Tumour microenvironment greyscale

TME image with poster tag

Explore our research poster modelling the tumour microenvironment featuring NK cells, macrophages and T cells.

Modelling the tumour microenvironment for the evaluation of new immuno-oncology therapies

IndEx-2 | Whitepaper 

<p>The release of our <strong>new inducible cell line development platform</strong>, <a target="_blank" rel="noopener noreferrer" href="https://cld.antibodyanalytics.com/index-2">IndEx-2</a>, has been a significant achievement for all the team at Antibody Analytics. Our innovative inducible <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/best-practices-in-cell-line-development">cell line development tool</a> can help to transform the drug discovery process of immune-directed therapies through the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies which enables the selection of candidates with improved efficacy and enhanced safety profiles at the discovery stage.</p><p>Leveraging the immune system is an effective strategy to combat cancer. However, at present there <strong>remains a need for </strong><i><strong>in vitro</strong></i><strong> systems</strong> to test the safety and efficacy of these modalities. Our team identified these challenges and whilst conducting our own research, we began developing the tool we know as <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/introducing-index-2-in-vitro-cell-based-platform">IndEx-2 </a>today.</p><p>In our latest whitepaper, we condense some of the key features of this new tool into a few pages, detailing the <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/index-2-pegs-boston-presentation">science and research behind IndEx-2</a>. We are excited to see how this innovative tool can be practically applied to a range of pre-clinical applications, so feel free to <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/contact-us">get in touch with our team</a> if it piqued your interest.</p><div class="raw-html-embed"><div class="center"><a href="https://share.hsforms.com/1DQX0IIU8SB2kaJTVPwaCgQ4v8st" target="_blank" class="external-btn-primary">Access our IndEx-2 whitepaper </a></div></div><p>&nbsp;</p><h2>Challenges IndEx-2 Can Help To Overcome</h2><p>Leveraging the immune system is a <strong>powerful anti-cancer strategy</strong> but achieving acceptable clinical safety remains challenging. One of the key barriers to developing effective immune activating / targeted therapeutics, such as <strong>immune cell engagers, chimeric antigen receptor (CAR) T cell therapies</strong> and <strong>antibody drug conjugates (ADCs),</strong> is the identification of a suitable cancer associated antigen. In most cases, the antigen(s) targeted are overexpressed by neoplastic cells, but also expressed, albeit to a lower level, in healthy tissues.</p><p>A further complication is the heterogeneity of expression, particularly in solid tumours. In many cases, this renders therapies ineffective due to low expression of the targeted receptor by a subset of cancer cells. Conversely, when the targeted antigen is expressed in healthy cells, the primary consideration is the development of <strong>“on-target, off-tumour” toxicities (OTOT)</strong>, that arise when non-malignant tissues are targeted.</p><p>Severe OTOT has been observed in various <strong>CAR-T clinical trials</strong> involving patients with solid tumours. These side effects constitute a significant safety hurdle for the successful development of these modalities, to the extent that there are <strong>FDA guidelines</strong> instructing the consideration of these side effects during the pre-clinical evaluation phase. These considerations also extend to other advanced therapeutics, including immune cell engagers and ADCs for which similar toxicities have been reported.</p><p><a target="_blank" rel="noopener noreferrer" href="https://share.hsforms.com/1DQX0IIU8SB2kaJTVPwaCgQ4v8st"><img src="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/Ind_Ex_2_Whitepaper_Hub_Spot_form_header_d3656f2e26.png" alt="IndEx-2 Whitepaper HubSpot form header.png" srcset="https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/thumbnail_Ind_Ex_2_Whitepaper_Hub_Spot_form_header_d3656f2e26.png 245w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/small_Ind_Ex_2_Whitepaper_Hub_Spot_form_header_d3656f2e26.png 500w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/medium_Ind_Ex_2_Whitepaper_Hub_Spot_form_header_d3656f2e26.png 750w,https://aa-website-content-bucket-prod.s3.eu-west-1.amazonaws.com/large_Ind_Ex_2_Whitepaper_Hub_Spot_form_header_d3656f2e26.png 1000w," sizes="100vw"></a></p><p>Current approaches assessing the impact of antigen density on <strong>therapeutic efficacy and safety</strong> rely on the use of cancer cell lines with varying antigen expression levels. However, establishing a large panel of such cell lines is logistically and methodologically difficult due to licensing costs, limited availability, and uncertainty around specific antigen expression levels.</p><p>Additionally, the varied backgrounds of these cell lines can confound data, as inherent genetic and epigenetic differences between these cell lines can render them susceptible, or resistant, to a potential therapeutic strategy that is independent of target antigen expression levels.</p><p>This highlights the need for improved <i>in vitro</i> systems to evaluate the effect of target antigen density on therapeutic efficacy and safety, earlier in the development process. With the introduction of the <strong>FDA Modernisation Act 2.0</strong>, advocating for the reduced animal model use, there is further impetus for the deployment of more cost-effective human models that can be implemented earlier in the drug discovery process.&nbsp;</p><p>Agile decision-making is easier at the pre-clinical stage, and the ability to pivot is more probable, having reduced cost implications in comparison to a clinical stage therapeutic candidate.</p><p>To find out more about the <strong>capabilities and features of our IndEx-2 platform</strong>, book a meeting with our scientific team.</p><div class="raw-html-embed"><div class="center"><a href="https://share.hsforms.com/1NI8r5BK2SU-URRbXleyCBA4v8st" target="_blank" class="external-btn-primary">Speak to a molecular scientist </a></div></div>

The background to IndEx-2 cell line development platform

IndEx-2 greyscale header 

IndEx-2 | Whitepaper | Greyscale image 

Find out more about our new inducible cell line development model IndEx-2 by reading through our latest whitepaper. 

IndEx-2: Deciphering the impact of antigen density on tumour targeting therapeutics

Agapitos_Patakas_author_100x100px.jpg

Human in vitro T cell exhaustion model

<p>At Antibody Analytics we are consistently striving to innovate and collaborate with other leaders in the industry, therefore we were honoured to be invited by Agilent to talk about our human T cell exhaustion model on SelectScience’s platform. We take pleasure in devising innovative solutions for challenging problems, and our human T cell exhaustion model is certainly no exception.<br><br>T cell exhaustion is central in the overall pathology of cancer however, there is an unmet need for a convenient, biologically relevant <i>in vitro</i> model of human T cell exhaustion. Most studies investigating <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news/t-cell-exhaustion-models-for-the-investigation-of-checkpoint-inhibitors">T cell exhaustion</a> employ mouse models of chronic viral infections e.g. LCMV. These are difficult and expensive to perform and, on most occasions, do not allow the assessment of human-targeting biologics.</p><p>Traditional T cell activation assays employing polyclonal stimuli e.g. SEB-activation, do not generate exhausted T cells and are therefore not reliable for the assessment of a candidate therapeutic’s impact on T cell exhaustion.<br>Here we present an <i>in vitro</i> model of chronic antigen stimulation that produces T cells with the phenotypic and functional characteristics of exhaustion.&nbsp;</p><p>We present high content data of the exhausted T cells characterized by <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/capabilities/our-equipment#novo-cyte-quanteon-flow-cytometer">multi-parameter flow cytometry</a> (Novocyte) and couple this with cytokine analysis. Functional assessments employ mixed lymphocyte reactions (MLRs) as a model for T cell activation, followed by kinetic assessment of T cell mediated cytotoxicity effector function using the xCELLigence RTCA.</p><p>Each comparing exhausted T cells with their non-exhausted counterparts in the presence of various therapeutics to assess their impact on this T cell state. This model is suitable for the screening of immuno-modulatory molecules, bispecific T cell engagers and multi-functional modalities.</p><p>Let’s look further into this human <a target="_blank" rel="noopener noreferrer" href="https://immunology.antibodyanalytics.com/t-cell-exhaustion"><i>in vitro</i> T cell exhaustion model</a> as presented by our CSO, Dr Agapitos Patakas:</p><div class="raw-html-embed"><div class="center"><iframe width="560" height="315" src="https://www.youtube.com/embed/2Q3sQ2bwwrI" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen=""></iframe></div></div><p><br>If you have any further questions about T cell exhaustion, or would like to get in touch with our scientific team, book a meeting with them here:&nbsp;</p><div class="raw-html-embed"><div class="center"><a href="https://meetings.hubspot.com/ahannigan1/30-minutes" target="_blank" class="external-btn-primary">Speak to a scientist</a></div></div><p>Stay tuned to our blog for the most <a target="_blank" rel="noopener noreferrer" href="https://antibodyanalytics.com/news">up-to-date news</a> and a wealth of additional scientific resources.</p>

T Cell Exhaustion image in greyscale style 

T Cell Exhaustion image in greyscale 

T cell exhaustion webinar resource image 

T Cell Exhaustion webinar image 

In this webinar, we present our own human in vitro T cell exhaustion model that is suitable for the screening of immuno-modulatory molecules, bispecific T cell engagers and multi-functional modalities. 

Presenting our human in vitro T cell exhaustion model | Webinar with Agilent on SelectScience 

<h2>The&nbsp;<span style="background-color:#32CDCD;color:hsl(0,0%,100%);"> Collaborative&nbsp;</span> immunology CRO</h2><p><span style="color:hsl(0,0%,0%);">Enriching your team</span></p>

home page carousel_cells_1.png

The Collaborative Immunology CRO

Antibody Analytics

<h2><span style="color:hsl(0,0%,0%);">The&nbsp;</span><span style="background-color:#6664ED;color:hsl(0,0%,100%);"> Creative&nbsp;</span><span style="color:hsl(0,0%,0%);"> immunology CRO</span></h2><p><span style="color:hsl(0,0%,0%);">Your challenge is our muse</span></p>

home page carousel_creative_2.png

The Creative Immunology CRO

<h2><span style="color:hsl(0,0%,0%);">The&nbsp;</span><span style="background-color:#FF1196;color:hsl(0,0%,100%);"> Consultative&nbsp;</span><span style="color:hsl(0,0%,0%);"> immunology CRO</span></h2><p><span style="color:hsl(0,0%,0%);">Sharing our solutions</span></p>

home page carousel_fur ball_3.png

The Consultative Immunology CRO

<p>Antibody Analytics Ltd.&nbsp;</p><p>VAT Number: GB 235 2396 11 | Registered in Scotland</p>

<h1>Our new revolutionary IndEx-2 system has launched</h1><p>A transformational, inducible cell system that allows selection of the safest and most efficacious targeted therapies. IndEx-2 is an <i>in vitro</i> cell-based platform that provides inducible <strong>expression of any target antigen of interest</strong> (TAOI).</p><ul><li><strong>Safety: </strong>Gain information on the potential of “on target, off tumour effects” via precise control of TAOI expression to model physiological and pathological expression levels</li><li><strong>Efficacy: </strong>Determine the antigen density activation threshold of targeted immunotherapies, including immune cell engagers, ADCs and engineered immune cell therapies</li></ul><p>IndEx-2 is an effective tool that can be used to enhance a pre-clinical data package with information that offers a more comprehensive understanding of a targeted drug <strong>mechanism of action</strong> and <strong>functional profile.&nbsp;</strong></p><p>&nbsp;</p><div class="raw-html-embed"><div class="left"><a href="https://cld.antibodyanalytics.com/index-2" target="_blank" class="external-btn-primary">Find out more</a></div></div>

horn.svg

Antibody Analytics - The Collaborative Immunology CRO

<h1>Meet us in person at upcoming events</h1><p>We’re so pleased to announce that in 2023 we’ll be exhibiting and presenting at these prestigious conferences:&nbsp;</p><ul><li><strong>Immuno-Oncology Summit Europe in London:</strong> 20-22nd June – stand 7</li></ul><p>&nbsp;</p><div class="raw-html-embed"><div class="left"><a href="https://share.hsforms.com/1YIM97zfBTGOnauA5PZapog4v8st" target="_blank" class="external-btn-primary">Find a suitable time to talk</a></div></div>

The Collaborative immunology CRO

Our new revolutionary IndEx-2 system has launched

News